2. Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-3) will be developed with support from Bayer and is currently recruiting patients.
11 Current Lymphoma Clinical Trials You Should Know About
2. Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-3) will be developed with support from Bayer and is currently recruiting patients.
